Quantcast
Last updated on April 18, 2014 at 16:52 EDT

BD Announces Results For 2012 Fourth Fiscal Quarter And Full Year

November 7, 2012

FRANKLIN LAKES, N.J., Nov. 7, 2012 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.967 billion for the fourth fiscal quarter ended September 30, 2012, representing a decrease of 1.1 percent from the prior-year period, or an increase of 4.7 percent on a foreign currency-neutral basis.

For the full fiscal year ended September 30, 2012, BD reported revenues of $7.708 billion, representing an increase of 1.6 percent over the prior-year period or 4.3 percent on a foreign currency-neutral basis.

“We are proud of our solid finish to 2012,” said Vincent A. Forlenza, Chairman of the Board, Chief Executive Officer and President. “Despite a challenging macroeconomic environment, we delivered on our financial and operating goals while continuing our ongoing investments in geographic expansion, new product platforms and strategic acquisitions. We believe we are well positioned to succeed and will continue to focus on our strategy of investing and innovating for growth. We are confident in our outlook for fiscal year 2013 and remain committed to delivering value to our customers and shareholders.”

Sale of Discovery Labware Unit, Excluding Advanced Bioprocessing
In April 2012, the Company signed a definitive agreement to sell its BD Biosciences – Discovery Labware unit, excluding its Advanced Bioprocessing platform, to Corning Incorporated. The results of operations associated with this disposal group have been reclassified as discontinued operations for all quarters and years referred to in this release. The transaction was completed on October 31, 2012 and the Company will record a gain within discontinued operations in the first quarter of fiscal year 2013.

Fourth Quarter and Analysis of the Full Fiscal Year 2012 and 2011 Earnings
Reported diluted earnings per share from continuing operations for the fourth quarter were $1.35, representing an increase of 4.7 percent over the prior-year period. Current quarter results included a charge of $20 million, or $0.07 per share from continuing operations, resulting from primarily non-cash pension settlements. The prior-year period results included a non-cash charge of $9 million, or $0.03 per share from continuing operations, resulting from the discontinuance of a research program within the Diagnostic Systems unit. Excluding these items, adjusted diluted earnings per share from continuing operations increased by 7.6 percent to $1.42, compared with $1.32 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fourth quarter increased by 15.2 percent.

For the full fiscal year ended September 30, 2012, reported diluted earnings per share from continuing operations were $5.30, representing a decrease of 0.2 percent over the prior-year period. Excluding the aforementioned charges of $0.06 per share from continuing operations in fiscal year 2012, and $0.03 per share from continuing operations in fiscal year 2011, adjusted diluted earnings per share from continuing operations increased by 0.8 percent to $5.37, compared with $5.33 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fiscal year increased 4.7 percent. On a full year basis, the charge of $20 million, or $0.06 per share from continuing operations, differs from the charge in the fourth quarter of $0.07 per share from continuing operations due to the number of average shares outstanding between the fourth quarter and full year.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.049 billion, representing a decrease of 0.5 percent compared with the prior-year period, or an increase of 5.9 percent on a currency-neutral basis. The segment’s revenue growth reflected strong sales across all three business units. For the twelve-month period ended September 30, 2012, BD Medical revenues increased 2.1 percent, or 5.1 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $645 million, representing an increase of 0.5 percent compared with the prior-year period, or 5.1 percent on a foreign currency-neutral basis. The segment’s growth was primarily driven by solid sales of Preanalytical Systems safety-engineered products and strong sales in the Diagnostic Systems unit, aided by the recent acquisition of KIESTRA. For the twelve-month period ended September 30, 2012, BD Diagnostics revenues increased 2.3 percent, or 4.5 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $273 million, representing a decrease of 6.3 percent compared with the prior-year period, or 0.7 percent on a foreign currency-neutral basis. Segment results continue to be negatively affected by weakness in the U.S. research market. For the twelve-month period ended September 30, 2012, BD Biosciences revenues decreased by 1.5 percent. On a foreign currency-neutral basis, revenues increased by 0.7 percent.

Geographic Results
Fourth quarter revenues in the U.S. were $824 million, representing an increase of 1.2 percent compared with the prior-year period. Revenues outside of the U.S. were $1.143 billion, representing a decrease of 2.6 percent compared with the prior-year period, or an increase of 7.1 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products. For the twelve-month period ended September 30, 2012, revenues in the U.S. were $3.288 billion, representing an increase of 1.2 percent compared with the prior-year period. Revenues outside of the U.S. were $4.421 billion, representing an increase of 1.9 percent compared with the prior-year period, or 6.6 percent on a foreign currency-neutral basis.

Fiscal 2013 Outlook for Full Year
The Company estimates that reported revenues for the full fiscal year 2013 will increase 2 to 3 percent, or about 3.5 to 4.5 percent on a foreign currency-neutral basis. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2013 to be between $5.58 and $5.64. On a currency-neutral basis, the Company expects diluted earnings per share from continuing operations to grow 7 to 8 percent, or 10 to 11 percent excluding the impact of the medical device tax that goes into effect in January 2013 under the U.S. healthcare reform law. The Company also plans to repurchase, subject to market conditions, about $500 million of its common stock in 2013.

Conference Call Information
A conference call regarding BD’s fourth quarter and full-year results and its expectations for the full fiscal year 2013 will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Wednesday, November 7, 2012. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Wednesday, November 14, 2012, access code 35734482.

Non-GAAP Financial Measures
This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5378
Colleen T. White, Corporate Communications – 201-847-5369

This press release, including the section entitled “Fiscal 2013 Outlook for Full Year”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers’ ability to provide products needed for our operations; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; changes in interest or foreign currency exchange rates; competitive factors; pricing and other market pressures; our ability to successfully integrate any businesses we acquire; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per share data)

                                                                                             Three Months Ended September 30,
                                                                                                       2012                     2011  % Change
                                                                                                       ----                     ----  --------

    REVENUES                                                                                     $1,967,171               $1,988,181            (1.1)

    Cost of products sold                                                                           966,345                  971,041            (0.5)
    Selling and administrative                                                                      484,259                  479,591             1.0
    Research and development                                                                        127,787                  124,528             2.6
    ------------------------                                                                        -------                  -------             ---
    TOTAL OPERATING COSTS
         AND EXPENSES                                                                             1,578,391                1,575,160             0.2
         ------------                                                                             ---------                ---------             ---

    OPERATING INCOME                                                                                388,780                  413,021            (5.9)

    Interest income                                                                                  11,954                    1,915              NM
    Interest expense                                                                                (35,292)                 (22,334)           58.0
    Other (expense) income, net                                                                      (3,543)                   1,272              NM
    ---------------------------                                                                      ------                    -----             ---

    INCOME FROM CONTINUING OPERATIONS BEFORE
         INCOME TAXES                                                                               361,899                  393,874            (8.1)

    Income tax provision                                                                             87,621                  108,827           (19.5)
    --------------------                                                                             ------                  -------           -----

    INCOME FROM CONTINUING OPERATIONS                                                               274,278                  285,047            (3.8)

    INCOME FROM DISCONTINUED OPERATIONS
       NET OF INCOME TAX PROVISION OF
                                                             $9,108 AND $8,860, RESPECTIVELY         14,765                   14,933            (1.1)
                                                             -------------------------------         ------                   ------            ----

    NET INCOME                                                                                     $289,043                 $299,980            (3.6)
    ----------                                                                                     --------                 --------            ----

    EARNINGS PER SHARE

    Basic:
    Income from continuing operations                                                                 $1.38                    $1.32             4.5
    Income from discontinued operations                                                               $0.07                    $0.07               -
    Net income (1)                                                                                    $1.45                    $1.38             5.1

    Diluted:
    Income from continuing operations                                                                 $1.35                    $1.29             4.7
    Income from discontinued operations                                                               $0.07                    $0.07               -
    Net income (1)                                                                                    $1.43                    $1.36             5.1

    AVERAGE SHARES OUTSTANDING

         Basic                                                                                      199,072                  216,726
         Diluted                                                                                    202,439                  220,859
         -------                                                                                    -------                  -------

    NM - Not Meaningful
    (1) Total per share amounts may not add due to rounding.

    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per share data)

                                                                                               Twelve Months Ended September 30,
                                                                                                         2012                     2011  % Change
                                                                                                         ----                     ----  --------

    REVENUES                                                                                       $7,708,382               $7,584,037             1.6

    Cost of products sold                                                                           3,755,388                3,625,122             3.6
    Selling and administrative                                                                      1,923,354                1,823,537             5.5
    Research and development                                                                          471,755                  469,517             0.5
    ------------------------                                                                          -------                  -------             ---
    TOTAL OPERATING COSTS
         AND EXPENSES                                                                               6,150,497                5,918,176             3.9
         ------------                                                                               ---------                ---------             ---

    OPERATING INCOME                                                                                1,557,885                1,665,861            (6.5)

    Interest income                                                                                    50,333                   43,209            16.5
    Interest expense                                                                                 (134,658)                 (84,019)           60.3
    Other expense, net                                                                                 (1,152)                  (7,164)          (83.9)
    ------------------                                                                                 ------                   ------           -----

    INCOME FROM CONTINUING OPERATIONS BEFORE
         INCOME TAXES                                                                               1,472,408                1,617,887            (9.0)

    Income tax provision                                                                              362,880                  417,004           (13.0)
    --------------------                                                                              -------                  -------           -----

    INCOME FROM CONTINUING OPERATIONS                                                               1,109,528                1,200,883            (7.6)

    INCOME FROM DISCONTINUED OPERATIONS
       NET OF INCOME TAX PROVISION OF
                                                             $31,268 AND $35,199, RESPECTIVELY         60,399                   70,111           (13.9)
                                                             ---------------------------------         ------                   ------           -----

    NET INCOME                                                                                     $1,169,927               $1,270,994            (8.0)
    ----------                                                                                     ----------               ----------            ----

    EARNINGS PER SHARE

    Basic:
    Income from continuing operations                                                                   $5.40                    $5.43            (0.6)
    Income from discontinued operations                                                                 $0.29                    $0.32            (9.4)
    Net income                                                                                          $5.69                    $5.75            (1.0)

    Diluted:
    Income from continuing operations                                                                   $5.30                    $5.31            (0.2)
    Income from discontinued operations                                                                 $0.29                    $0.31            (6.5)
    Net income                                                                                          $5.59                    $5.62            (0.5)

    AVERAGE SHARES OUTSTANDING

         Basic                                                                                        205,460                  221,175
         Diluted                                                                                      209,181                  226,280
         -------                                                                                      -------                  -------
    Becton Dickinson and Company
    Supplemental Income Statement Information - Fiscal 2012
    Revised for discontinued operations of Discovery Labware divestiture
    (Unaudited: Amounts in thousands, except per-share data)

                                                            Amounts
                                                        reclassified to                   From
                                                          Discontinued                 Continuing
                                 Pro Forma                 Operations                  Operations
                                 ---------                 ----------                  ----------
    Quarter 1
    ---------
    Revenues                                $1,887,645                         $55,925            $1,831,720
    Income                                    $263,010                         $14,466              $248,544
    Diluted
     Earnings
     Per Share                                   $1.21                           $0.07                 $1.14

    Quarter 2
    ---------
    Revenues                                $1,990,818                         $61,857            $1,928,961
    Income                                    $290,548                         $15,424              $275,124
    Diluted
     Earnings
     Per Share                                   $1.38                           $0.07                 $1.31

    Quarter 3
    ---------
    Revenues                                $2,040,760                         $60,230            $1,980,530
    Income                                    $326,795                         $15,214              $311,581
    Diluted
     Earnings
     Per Share                                   $1.59                           $0.07                 $1.52

    Quarter 4
    ---------
    Revenues                                $2,027,335                         $60,164            $1,967,171
    Income                                    $289,099                         $14,821              $274,278
    Diluted
     Earnings
     Per Share
     (1)                                         $1.43                           $0.07                 $1.35

    YTD
    ---
    Revenues                                $7,946,559                        $238,177            $7,708,382
    Income                                  $1,169,453                         $59,925            $1,109,528
    Diluted
     Earnings
     Per Share                                   $5.59                           $0.29                 $5.30

    Certain quarterly amounts may not add to the year-to-date totals due to rounding.
    (1) Diluted Earnings per Share may not add due to rounding.

    Becton Dickinson and Company
    Supplemental Income Statement Information - Fiscal 2011 and 2010
    Revised for discontinued operations of Discovery Labware divestiture
    (Unaudited: Amounts in thousands, except per-share data)

                                                                             Amounts
                                                                         reclassified to             From
                                                                           Discontinued           Continuing
                                                     Pro Forma              Operations            Operations
                                                     ---------              ----------            ----------
    Fiscal 2011
    -----------
    Revenues                                                $7,828,904                   $244,867          $7,584,037
    Income                                                  $1,264,852                    $63,969          $1,200,883
    Diluted
     Earnings
     Per Share                                                   $5.59                      $0.28               $5.31

    Fiscal 2010
    -----------
    Revenues                                                $7,372,333                   $247,948          $7,124,385
    Income                                                  $1,176,340                    $61,496          $1,114,844
    Diluted
     Earnings
     Per Share                                                   $4.90                      $0.26               $4.64

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)

                                            Three Months Ended September 30,
                                                                          2012       2011 % Change
                                                                          ----       ---- --------

    BD
     MEDICAL
    --------
        United
        States                                                        $422,290   $404,301           4.4
       International                                                   626,742    650,290          (3.6)
       -------------                                                   -------    -------
    TOTAL                                                           $1,049,032 $1,054,591          (0.5)
    -----                                                           ---------- ----------          ----

    BD
     DIAGNOSTICS
    ------------
        United
        States                                                        $313,916   $313,603           0.1
       International                                                   331,128    328,445           0.8
       -------------                                                   -------    -------
    TOTAL                                                             $645,044   $642,048           0.5
    -----                                                             --------   --------           ---

    BD
     BIOSCIENCES
    ------------
        United
        States                                                         $87,651    $96,543          (9.2)
       International                                                   185,444    194,999          (4.9)
       -------------                                                   -------    -------
    TOTAL                                                             $273,095   $291,542          (6.3)
    -----                                                             --------   --------          ----

     TOTAL
     REVENUES
     --------
        United
        States                                                        $823,857   $814,447           1.2
       International                                                 1,143,314  1,173,734          (2.6)
       -------------                                                 ---------  ---------
    TOTAL                                                           $1,967,171 $1,988,181          (1.1)
    -----                                                           ---------- ----------          ----
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)

                                            Twelve Months Ended September 30,
                                                        2012                     2011 % Change
                                                        ----                     ---- --------

    BD MEDICAL
    ----------
       United States                            $1,685,101               $1,625,044       3.7
       International                             2,405,592                2,382,260       1.0
       -------------                             ---------                ---------
    TOTAL                                       $4,090,693               $4,007,304       2.1
    -----                                       ----------               ----------       ---

    BD DIAGNOSTICS
    --------------
       United States                            $1,259,376               $1,245,872       1.1
       International                             1,278,679                1,234,605       3.6
       -------------                             ---------                ---------
    TOTAL                                       $2,538,055               $2,480,477       2.3
    -----                                       ----------               ----------       ---

    BD BIOSCIENCES
    --------------
       United States                              $343,238                 $376,639      (8.9)
       International                               736,396                  719,617       2.3
       -------------                               -------                  -------
    TOTAL                                       $1,079,634               $1,096,256      (1.5)
    -----                                       ----------               ----------      ----

    TOTAL REVENUES
    --------------
       United States                            $3,287,715               $3,247,555       1.2
       International                             4,420,667                4,336,482       1.9
       -------------                             ---------                ---------
    TOTAL                                       $7,708,382               $7,584,037       1.6
    -----                                       ----------               ----------       ---

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30,
    (Unaudited; Amounts in thousands)

                                                            United States
                                                            -------------
                                                              2012                   2011           % Change
                                                              ----                   ----          --------

    BD MEDICAL
    ----------
       Medical Surgical
        Systems                                         $250,664               $246,746                1.6
       Diabetes Care                                     113,046                104,819                7.8
       Pharmaceutical Systems                             58,580                 52,736               11.1
    TOTAL                                               $422,290               $404,301                4.4
    -----                                               --------               --------                ---

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                            $164,856               $161,556                2.0
       Diagnostic Systems                                149,060                152,047               (2.0)
       ------------------                                -------                -------
    TOTAL                                               $313,916               $313,603                0.1
    -----                                               --------               --------                ---

    BD BIOSCIENCES (1)                                   $87,651                $96,543               (9.2)
    -----------------                                    -------                -------               ----

    TOTAL UNITED STATES                                 $823,857               $814,447                1.2
    -------------------                                 --------               --------                ---

    (1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform.
        Advanced Bioprocessing was previously reported with the Discovery Labware unit.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)

                                                                                                 International
                                                                                                 -------------
                                                                                                                                                  % Change
                                                                                                                                                 --------
                                                                         2012                     2011               Reported       FXN      FX Impact
                                                                         ----                     ----              --------        ---      ---------

    BD MEDICAL
    ----------
       Medical Surgical Systems                                                   $281,603                 $288,653           (2.4)      6.8                (9.2)
       Diabetes Care                                                               120,391                  119,832            0.5       9.8                (9.3)
       Pharmaceutical Systems                                                      224,748                  241,805           (7.1)      5.3               (12.4)
                                                                                                                                                           -----
    TOTAL                                                                         $626,742                 $650,290           (3.6)      6.8               (10.4)
    -----                                                                         --------                 --------           ----       ---               -----

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                                                      $162,648                 $167,044           (2.6)      7.3                (9.9)
       Diagnostic Systems                                                          168,480                  161,401            4.4      12.7                (8.3)
       ------------------
    TOTAL                                                                         $331,128                 $328,445            0.8       9.9                (9.1)
    -----                                                                         --------                 --------            ---       ---                ----

    BD BIOSCIENCES (1)                                                            $185,444                 $194,999           (4.9)      3.5                (8.4)
    -----------------                                                             --------                 --------           ----       ---                ----

    TOTAL INTERNATIONAL                                                         $1,143,314               $1,173,734           (2.6)      7.1                (9.7)
    -------------------                                                         ----------               ----------           ----       ---                ----

    (1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform.
        Advanced Bioprocessing was previously reported with the Discovery Labware unit.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)

                                                                                                     Total
                                                                                                     -----
                                                                                                                                                   % Change
                                                                                                                                                  --------
                                                                         2012                     2011               Reported       FXN       FX Impact
                                                                         ----                     ----              --------        ---       ---------

    BD MEDICAL
    ----------
       Medical Surgical Systems                                                   $532,267                 $535,399           (0.6)      4.4                 (5.0)
       Diabetes Care                                                               233,437                  224,651            3.9       8.9                 (5.0)
       Pharmaceutical Systems                                                      283,328                  294,541           (3.8)      6.4                (10.2)
    TOTAL                                                                       $1,049,032               $1,054,591           (0.5)      5.9                 (6.4)
    -----                                                                       ----------               ----------           ----       ---                 ----

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                                                      $327,504                 $328,600           (0.3)      4.7                 (5.0)
       Diagnostic Systems                                                          317,540                  313,448            1.3       5.6                 (4.3)
       ------------------
    TOTAL                                                                         $645,044                 $642,048            0.5       5.1                 (4.6)
    -----                                                                         --------                 --------            ---       ---                 ----

    BD BIOSCIENCES (1)                                                            $273,095                 $291,542           (6.3)     (0.7)                (5.6)
    -----------------                                                             --------                 --------           ----      ----                 ----

    TOTAL REVENUES                                                              $1,967,171               $1,988,181           (1.1)      4.7                 (5.8)
    --------------                                                              ----------               ----------           ----       ---                 ----

    (1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform.
        Advanced Bioprocessing was previously reported with the Discovery Labware unit.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30,
    (Unaudited; Amounts in thousands)

                                                                                      United States
                                                                                      -------------
                                                                                        2012                2011  % Change
                                                                                        ----                ---- --------

    BD MEDICAL
    ----------
       Medical Surgical Systems                                                   $977,999            $980,326      (0.2)
       Diabetes Care                                                               434,310             400,809       8.4
       Pharmaceutical Systems                                                      272,792             243,909      11.8
    TOTAL                                                                       $1,685,101          $1,625,044       3.7
    -----                                                                       ----------          ----------       ---

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                                                      $656,389            $643,180       2.1
       Diagnostic Systems                                                          602,987             602,692       0.0
       ------------------                                                          -------             -------
    TOTAL                                                                       $1,259,376          $1,245,872       1.1
    -----                                                                       ----------          ----------       ---

    BD BIOSCIENCES  (1)                                                           $343,238            $376,639      (8.9)
    ------------------                                                            --------            --------      ----

    TOTAL UNITED STATES                                                         $3,287,715          $3,247,555       1.2
    -------------------                                                         ----------          ----------       ---

    (1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform.
        Advanced Bioprocessing was previously reported with the Discovery Labware unit.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)

                                                                                                 International
                                                                                                 -------------
                                                                                                                                                 % Change
                                                                                                                                                --------
                                                                         2012                     2011               Reported       FXN     FX Impact
                                                                         ----                     ----              --------        ---     ---------

    BD MEDICAL
    ----------
       Medical Surgical Systems                                                 $1,127,289               $1,101,407            2.3      6.9               (4.6)
       Diabetes Care                                                               476,966                  465,668            2.4      6.8               (4.4)
       Pharmaceutical Systems                                                      801,337                  815,185           (1.7)     4.4               (6.1)
    TOTAL                                                                       $2,405,592               $2,382,260            1.0      6.1               (5.1)
    -----                                                                       ----------               ----------            ---      ---               ----

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                                                      $644,503                 $634,613            1.6      6.7               (5.1)
       Diagnostic Systems                                                          634,176                  599,992            5.7      9.4               (3.7)
       ------------------
    TOTAL                                                                       $1,278,679               $1,234,605            3.6      8.0               (4.4)
    -----                                                                       ----------               ----------            ---      ---               ----

    BD BIOSCIENCES (1)                                                            $736,396                 $719,617            2.3      5.8               (3.5)
    -----------------                                                             --------                 --------            ---      ---               ----

    TOTAL INTERNATIONAL                                                         $4,420,667               $4,336,482            1.9      6.6               (4.7)
    -------------------                                                         ----------               ----------            ---      ---               ----

    (1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform.
        Advanced Bioprocessing was previously reported with the Discovery Labware unit.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)

                                                                                                     Total
                                                                                                     -----
                                                                                                                                                 % Change
                                                                                                                                                --------
                                                                         2012                     2011               Reported       FXN     FX Impact
                                                                         ----                     ----              --------        ---     ---------

    BD MEDICAL
    ----------
       Medical Surgical Systems                                                 $2,105,288               $2,081,733            1.1      3.6               (2.5)
       Diabetes Care                                                               911,276                  866,477            5.2      7.5               (2.3)
       Pharmaceutical Systems                                                    1,074,129                1,059,094            1.4      6.2               (4.8)
    TOTAL                                                                       $4,090,693               $4,007,304            2.1      5.1               (3.0)
    -----                                                                       ----------               ----------            ---      ---               ----

    BD DIAGNOSTICS
    --------------
       Preanalytical Systems                                                    $1,300,892               $1,277,793            1.8      4.3               (2.5)
       Diagnostic Systems                                                        1,237,163                1,202,684            2.9      4.7               (1.8)
       ------------------
    TOTAL                                                                       $2,538,055               $2,480,477            2.3      4.5               (2.2)
    -----                                                                       ----------               ----------            ---      ---               ----

    BD BIOSCIENCES  (1)                                                         $1,079,634               $1,096,256           (1.5)     0.7               (2.2)
    ------------------                                                          ----------               ----------           ----      ---               ----

    TOTAL REVENUES                                                              $7,708,382               $7,584,037            1.6      4.3               (2.7)
    --------------                                                              ----------               ----------            ---      ---               ----

    (1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform.
        Advanced Bioprocessing was previously reported with the Discovery Labware unit.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    SAFETY REVENUES
    (Unaudited; Amounts in thousands)

                                                  Three Months Ended September 30,
                                                  --------------------------------
                                                                                                              % Change
                                                                                                             --------
                                      2012                   2011                Reported      FXN       FX Impact
                                      ----                   ----               --------       ---       ---------

    TOTAL SAFETY REVENUES
    ---------------------
       United States                         $291,046                 $288,541             0.9      0.9                   -
       International                          215,595                  209,209             3.1     12.7                (9.6)
       -------------                          -------                  -------             ---                         ----
    TOTAL                                    $506,641                 $497,750             1.8      5.8                (4.0)
    -----                                    --------                 --------             ---      ---                ----

    BY SEGMENT
    ----------
       BD Medical                            $250,676                 $243,521             2.9      6.4                (3.5)
       BD Diagnostics                         255,965                  254,229             0.7      5.3                (4.6)
       --------------                         -------                  -------             ---                         ----
    TOTAL                                    $506,641                 $497,750             1.8      5.8                (4.0)
    -----                                    --------                 --------             ---      ---                ----

                                                Twelve Months Ended September 30,
                                                ---------------------------------
                                                                                                       % Change
                                                                                                      --------
                                      2012                   2011                Reported      FXN       FX Impact
                                      ----                   ----               --------       ---       ---------

    TOTAL SAFETY REVENUES
    ---------------------
       United States                       $1,149,220               $1,116,543             2.9      2.9                   -
       International                          833,886                  754,739            10.5     15.6                (5.1)
       -------------                          -------                  -------            ----                         ----
    TOTAL                                  $1,983,106               $1,871,282             6.0      8.0                (2.0)
    -----                                  ----------               ----------             ---      ---                ----

    BY SEGMENT
    ----------
       BD Medical                            $966,452                 $885,156             9.2     10.8                (1.6)
       BD Diagnostics                       1,016,654                  986,126             3.1      5.6                (2.5)
       --------------                       ---------                  -------             ---                         ----
    TOTAL                                  $1,983,106               $1,871,282             6.0      8.0                (2.0)
    -----                                  ----------               ----------             ---      ---                ----

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    FY2012 Quarter-to-Date Reconciliation
    (Unaudited; Amounts in millions, except per share data)

                                                                                                             Three Months Ended September 30,
                                                                                                             --------------------------------
                                                                     Reported                   Pension                   Adjusted              Reported       Impairment      Adjusted       Adjusted
                                                                                              Settlement
                                                                      FY 2012                  Charge(1)                   FY 2012               FY 2011       Charge(2)        FY 2011        %Growth
                                                                      -------                  --------                    -------               -------        --------        -------        -------

    Diluted Earnings per Share
    from Continuing Operations                                                        $1.35                      $0.07                    $1.42          $1.29            0.03          $1.32          7.6%

    (1) Primarily represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's
        U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year.
        The charge also included settlement losses associated with certain foreign pension plans.

    (2)Represents a non-cash impairment charge resulting from the discontinuance of a research program within the Diagnostic Systems unit.

    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    FY2012 Year-to-Date Reconciliation
    (Unaudited; Amounts in millions, except per share data)

                                                                                                              Twelve Months Ended September 30,
                                                                                                              ---------------------------------
                                                                     Reported                   Pension                   Adjusted              Reported       Impairment       Adjusted       Adjusted
                                                                                              Settlement
                                                                      FY 2012                  Charge(1)                   FY 2012               FY 2011        Charge(2)        FY 2011        %Growth
                                                                      -------                  --------                    -------               -------        --------         -------        -------

    Diluted Earnings per Share
    from Continuing Operations                                                        $5.30                      $0.06                    $5.37          $5.31            $0.03          $5.33          0.8%

    (1) Primarily represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's
        U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year.
        The charge also included settlement losses associated with certain foreign pension plans.

    (2)Represents a non-cash impairment charge resulting from the
        discontinuance of a research program within the Diagnostic Systems unit.

    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    Quarter-to-Date Fiscal 2012 Reconciliation - FX Impact
    (Unaudited; Amounts in millions, except per share data)

                                                                               Three Months Ended September 30,
                                                                               --------------------------------
                                                             Adjusted        Adjusted                 Adjusted             Foreign            FXN           FXN
                                                                                                       Growth             Currency
                                                              FY 2012         FY 2011                          $        Translation          Change       Growth
                                                              -------         -------                        ---        -----------         ------        ------

    REVENUES                                                          $1,967                $1,988                $(21)              $(114)           $93         4.7%

    Diluted Earnings per Share
    from Continuing Operations                                         $1.42                 $1.32               $0.10              $(0.10)         $0.20        15.2%

    FXN - Foreign Currency Neutral
    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    Year-to-Date Fiscal 2012 Reconciliation - FX Impact
    (Unaudited; Amounts in millions, except per share data)

                                                                              Twelve Months Ended September 30,
                                                                              ---------------------------------
                                                             Adjusted        Adjusted                 Adjusted            Foreign            FXN           FXN
                                                                                                       Growth            Currency
                                                              FY 2012         FY 2011                          $       Translation          Change       Growth
                                                              -------         -------                        ---       -----------         ------        ------

    REVENUES                                                          $7,708                $7,584                $124              $(200)          $325        4.3%

    Diluted Earnings per Share
    from Continuing Operations                                         $5.37                 $5.33               $0.04             $(0.21)         $0.25        4.7%

    FXN - Foreign Currency Neutral
    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    FY2013 Outlook Reconciliation
                                  EPS        Revenues
                                  ---        --------
    Growth                             4-5%              2-3%
    FX impact                           (3%)             (1.5%)
                                        ---              -----
    FX neutral growth                  7-8%         3.5%-4.5%
    Device tax impact                   (3%)
                                        ---
                                     10-11%

SOURCE BD (Becton, Dickinson and Company)


Source: PR Newswire